Literature DB >> 7479913

Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.

M Satoh1, A Kumar, Y S Kanwar, W H Reeves.   

Abstract

The pathogenesis of systemic lupus erythematosus is thought to be primarily under genetic control, with environmental factors playing a secondary role. However, it has been shown recently that intraperitoneal injection of pristane (2,6,10,14-tetramethylpentadecane) induces autoantibodies typical of lupus in BALB/c mice, a strain not usually considered to be genetically susceptible to the disease. In this study, the induction of autoimmune disease by pristane was investigated. BALB/c mice receiving pristane were tested for autoantibody production and histopathological evidence of glomerulonephritis. Six of 11 mice developed IgM anti-single-stranded DNA antibodies shortly after receiving pristane and 4 developed IgM anti-histone antibodies, but anti-double-stranded DNA antibodies were absent. IgG anti-DNA and anti-histone antibodies were absent. In contrast, the lupus-associated anti-nuclear ribonucleoprotein/Sm and anti-Su autoantibodies produced by these mice were predominantly IgG. In addition to autoantibodies, most of the mice developed significant proteinuria. Light microscopy of the kidney showed segmental or diffuse proliferative glomerulonephritis. Electron microscopy showed subepithelial and mesangial immune-complex deposits and epithelial foot process effacement. Immunofluorescence revealed striking glomerular deposition of IgM, IgG, and C3 with a mesangial or mesangiocapillary distribution. Thus, pristane induces immune-complex glomerulonephritis in association with autoantibodies typical of lupus in BALB/c mice. These data support the idea that lupus is produced by an interplay of genetic and environmental factors and that unlike the MRL or (NZB x W)F1 mouse models, in which genetic susceptibility factors are of primary importance, environmental factors are of considerable importance in the autoimmune disease of pristane-treated BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479913      PMCID: PMC40545          DOI: 10.1073/pnas.92.24.10934

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Loss of CD23 is a consequence of B-cell activation. Implications for the analysis of B-cell lineages.

Authors:  E Rabin; Y Z Cong; H H Wortis
Journal:  Ann N Y Acad Sci       Date:  1992-05-04       Impact factor: 5.691

2.  Anti-nucleic acid specificites of mouse myeloma immunoglobulins.

Authors:  D Schubert; A Roman; M Cohn
Journal:  Nature       Date:  1970-01-10       Impact factor: 49.962

3.  Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin.

Authors:  E Shacter; G K Arzadon; J Williams
Journal:  Blood       Date:  1992-07-01       Impact factor: 22.113

Review 4.  Anti-DNA antibodies in systemic lupus erythematosus.

Authors:  D S Pisetsky
Journal:  Rheum Dis Clin North Am       Date:  1992-05       Impact factor: 2.670

5.  Involvement of IL-6 in mesangial proliferative glomerulonephritis.

Authors:  Y Horii; A Muraguchi; M Iwano; T Matsuda; T Hirayama; H Yamada; Y Fujii; K Dohi; H Ishikawa; Y Ohmoto
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

6.  Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10.

Authors:  A O'Garra; R Chang; N Go; R Hastings; G Haughton; M Howard
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

7.  Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites.

Authors:  D V Vlahakos; M H Foster; S Adams; M Katz; A A Ucci; K J Barrett; S K Datta; M P Madaio
Journal:  Kidney Int       Date:  1992-06       Impact factor: 10.612

8.  Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci.

Authors:  M L Watson; J K Rao; G S Gilkeson; P Ruiz; E M Eicher; D S Pisetsky; A Matsuzawa; J M Rochelle; M F Seldin
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

9.  Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes.

Authors:  S Izui; P H Lambert; G J Fournié; H Türler; P A Miescher
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice.

Authors:  E A Reap; E S Sobel; P L Cohen; R A Eisenberg
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

View more
  72 in total

1.  Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane.

Authors:  M Satoh; H B Richards; V M Shaheen; H Yoshida; M Shaw; J O Naim; P H Wooley; W H Reeves
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Therapeutic effect of Withania somnifera on pristane-induced model of SLE.

Authors:  Ujla Minhas; Ranjana Minz; Prabir Das; Archana Bhatnagar
Journal:  Inflammopharmacology       Date:  2011-12-13       Impact factor: 4.473

3.  Lupus Nephritis: Animal Modeling of a Complex Disease Syndrome Pathology.

Authors:  Tracy L McGaha; Michael P Madaio
Journal:  Drug Discov Today Dis Models       Date:  2014

4.  B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus.

Authors:  Dina C Nacionales; Jason S Weinstein; Xiao-Jie Yan; Emilia Albesiano; Pui Y Lee; Kindra M Kelly-Scumpia; Robert Lyons; Minoru Satoh; Nicholas Chiorazzi; Westley H Reeves
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

5.  Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.

Authors:  C Liu; Y Kanamaru; T Watanabe; N Tada; S Horikoshi; Y Suzuki; Z Liu; Y Tomino
Journal:  Clin Exp Immunol       Date:  2015-07-02       Impact factor: 4.330

6.  A Novel Mechanism for Generating the Interferon Signature in Lupus: Opsonization of Dead Cells by Complement and IgM.

Authors:  Haoyang Zhuang; Shuhong Han; Yi Li; Deborah Kienhöfer; Pui Lee; Stepan Shumyak; Richard Meyerholz; Krzysztof Rosadzinski; Danielle Rosner; Annie Chan; Yuan Xu; Mark Segal; Eric Sobel; Li-Jun Yang; Markus H Hoffmann; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

7.  Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.

Authors:  Deborah Kienhöfer; Jonas Hahn; Julia Stoof; Janka Zsófia Csepregi; Christiane Reinwald; Vilma Urbonaviciute; Caroline Johnsson; Christian Maueröder; Malgorzata J Podolska; Mona H Biermann; Moritz Leppkes; Thomas Harrer; Malin Hultqvist; Peter Olofsson; Luis E Munoz; Attila Mocsai; Martin Herrmann; Georg Schett; Rikard Holmdahl; Markus H Hoffmann
Journal:  JCI Insight       Date:  2017-05-18

8.  Increased susceptibility against Cryptococcus neoformans of lupus mouse models (pristane-induction and FcGRIIb deficiency) is associated with activated macrophage, regardless of genetic background.

Authors:  Saowapha Surawut; Jiradej Makjaroen; Arthid Thim-Uam; Jutamas Wongphoom; Tanapat Palaga; Prapaporn Pisitkun; Ariya Chindamporn; Asada Leelahavanichkul
Journal:  J Microbiol       Date:  2018-11-19       Impact factor: 3.422

9.  Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.

Authors:  Hideo Yoshida; Minoru Satoh; Krista M Behney; Chee-Gun Lee; Hanno B Richards; Victoria M Shaheen; Jun-Qi Yang; Ram R Singh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2002-08

10.  IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.

Authors:  Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.